Meeting
2020 ASCO Virtual Scientific Program
A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).
Authors
Matthew Ingham
Columbia University Irving Medical Center, New York, NY
Matthew Ingham , Michelle R. Mahoney , Fabrizio Remotti , Ardaman Shergill , Mark Andrew Dickson , Richard F. Riedel , Steven Attia , Anthony D. Elias , David A. Liebner , Mark Agulnik , Katherine Anne Thornton , Varun Monga , Brian Andrew Van Tine , Gary K. Schwartz , William D. Tap
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02601209
Citation
J Clin Oncol 38: 2020 (suppl; abstr 11562)
DOI
10.1200/JCO.2020.38.15_suppl.11562
Abstract #
11562
Poster Bd #
450
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2014 ASCO Annual Meeting
Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.
First Author: Vicky Makker
Poster
2022 ASCO Annual Meeting
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
First Author: Jennifer Rachel Eads